There is a rapidly growing split of authority among courts as to whether FDA regulation of generic drug labeling preempts state-law failure-to-warn claims. This article examines the continuing viability of a preemption defense in pharmaceutical product liability cases alleging the defective labeling of generic drugs in the wake of Levine.
Firefox recommends the PDF Plugin for Mac OS X for viewing PDF documents in your browser.
We can also show you Legal Updates using the Google Viewer; however, you will need to be logged into Google Docs to view them.
Please choose one of the above to proceed!
LOADING PDF: If there are any problems, click here to download the file.